Investor’s Update: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

[PRNewswire] Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced that Leonard Bell, M.D. has been appointed Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby, who was voted Lead Independent Director by the other independent members of the Board, has been a Director of Alexion since September 1999.Stock PerformanceTaking a look at the company’s recent performance, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reported second quarter earnings for fiscal 2014 on July 24^th. The company reported actual earnings per share of $1.12 against the consensus Street estimate of $1.07. This represents year over year growth of 34.8%. Alexion posted revenue of $509.54 billion against estimates of $509.22 billion. Alexion is currently valued at $32.81 billion and closed the last trading session at $165.88. The stock has a 50-day moving average of $166.07 and a 200-day moving average of $161.15.Is this a Buying Opportunity?There are currently sixteen analysts that we track that cover the stock. Of those sixteen, eleven have a Buy rating and five have a hold rating. On a consensus basis this yields a score of 2.69 and a Buy. The combined price objective of these covering analysts is $186.29, which represents a 11.42% upside difference to the last closing price. The most recent analyst activity consisted of Bank of America Initiated Coverage with buy stance on the company. Bank of America has a price target of $197 which represents an upside of 18% from the last closing price. On the date of the report, the stock closed at $167.20.Another research firm weighing in recently was Zacks who also initiated coverage on the stock. On September 23^rd Zacks released price target on the stock of $168, or a 0.78% upside to the current price. On the day of the report, ALXN shares closed at $158.67.Company ProfileAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN), a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease.